Literature DB >> 30809806

Neuroprotective effect of pharmacological postconditioning on cerebral ischaemia-reperfusion-induced injury in mice.

Amarjot Kaur Grewal1, Nirmal Singh2, Thakur Gurjeet Singh1.   

Abstract

OBJECTIVES: To investigate the mechanism of neuroprotection rendered via pharmacological postconditioning in cerebral ischaemia-reperfusion-induced injury in mice.
METHODS: Pharmacological postconditioning is strategy which either involves hindering deleterious pathway or inducing modest stress level which triggers intracellular defence pathway to sustain more vigorous insult leading to conditioning. Hence, in current research we explored the potentiality of CGS21680 (0.5 mg/kg; i.p), an adenosine A2 A receptor agonist and PTEN inhibitor, SF1670 (3 mg/kg; i.p.) to trigger postconditioning after inducing cerebral global ischaemia (17 min) and reperfusion (24 h)-induced injury via occlusion of both carotid arteries. Mice were also given treatment with LY294002 (1.5 mg/kg; i.p.), a PI3K inhibitor and adenosine A2 A receptor antagonist, Istradefylline (2 mg/kg; i.p.), to establish the precise mechanism of postconditioning. Various biochemical and behavioural parameters were assessed to examine the effect of pharmacological postconditioning. KEY
FINDINGS: Pharmacological postconditioning induced with CGS21680 and SF1670 attenuated the infarction along with improved behavioural and biochemical parameters in comparison with ischaemia-reperfusion control group. The outcome of postconditioning with CGS21680 and SF1670 was significantly reversed by LY294002 and Istradefylline, respectively.
CONCLUSIONS: The neuroprotective effects of CGS21680 and SF1670 postconditioning on cerebral ischaemia-reperfusion injury may be due to PI3K/Akt pathway activation.
© 2019 Royal Pharmaceutical Society.

Entities:  

Keywords:  LY294002; PI3K; global cerebral ischaemia; istradefylline; pharmacological postconditioning

Mesh:

Substances:

Year:  2019        PMID: 30809806     DOI: 10.1111/jphp.13073

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

1.  Emerging perspectives on mitochondrial dysfunctioning and inflammation in epileptogenesis.

Authors:  Shareen Singh; Thakur Gurjeet Singh
Journal:  Inflamm Res       Date:  2021-10-15       Impact factor: 4.575

2.  Neuroprotective Effect of Piclamilast-Induced Post-Ischemia Pharmacological Treatment in Mice.

Authors:  Amarjot Kaur; Thakur Gurjeet Singh; Heena Khan; Manish Kumar; Nirmal Singh; Mohamed M Abdel-Daim
Journal:  Neurochem Res       Date:  2022-04-28       Impact factor: 4.414

Review 3.  Caffeine and Its Neuroprotective Role in Ischemic Events: A Mechanism Dependent on Adenosine Receptors.

Authors:  R Brito; K C Calaza; D Pereira-Figueiredo; A A Nascimento; M C Cunha-Rodrigues
Journal:  Cell Mol Neurobiol       Date:  2021-03-17       Impact factor: 5.046

Review 4.  Traumatic Brain Injury: Mechanistic Insight on Pathophysiology and Potential Therapeutic Targets.

Authors:  Komal Thapa; Heena Khan; Thakur Gurjeet Singh; Amarjot Kaur
Journal:  J Mol Neurosci       Date:  2021-05-06       Impact factor: 3.444

Review 5.  Mechanistic insight on the role of leukotriene receptors in ischemic-reperfusion injury.

Authors:  Heena Khan; Anjali Gupta; Thakur Gurjeet Singh; Amarjot Kaur
Journal:  Pharmacol Rep       Date:  2021-04-05       Impact factor: 3.024

Review 6.  Peroxisome Proliferator-Activated Receptor-Gamma (PPAR-ɣ): Molecular Effects and Its Importance as a Novel Therapeutic Target for Cerebral Ischemic Injury.

Authors:  Ashi Mannan; Nikhil Garg; Thakur Gurjeet Singh; Harmeet Kaur Kang
Journal:  Neurochem Res       Date:  2021-07-20       Impact factor: 3.996

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.